Applied Ventures invested in the Ultivue as part of a series B round that will be used to develop its biomarker detection technology.
US-based biological imaging system developer Ultivue has completed a $20m series B round led by venture capital firm Arch Venture Partners and backed by semiconductor equipment manufacturer Applied Materials.
The round included 6 Dimensions Capital, the investment vehicle formed by medical research firm WuXi PharmaTech’s corporate venturing arm, WuXi Healthcare Ventures, and VC firm Frontline BioVentures, as well as Yonghua Capital and Sangel Capital. Applied Materials invested through its Applied Ventures unit.
Ultivue is developing an imaging system to…